Nutritional intervention to prevent weight gain in patients commenced on olanzapine: A randomized controlled trial

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 6, 2005, Pages 479-486

  Evans, Sherryn ^a   Newton, Richard ^a,b   Higgins, Sally ^a  

^a FRANKSTON HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antipsychotics; Dietitian; Nutrition; Olanzapine; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; AUSTRALIA; BODY IMAGE; BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FEMALE; HEALTH EDUCATION; HUMAN; MALE; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NUTRITION; OBESITY; PREVALENCE; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; BENZODIAZEPINES; BIPOLAR DISORDER; BODY IMAGE; BODY MASS INDEX; DEPRESSIVE DISORDER, MAJOR; EXERCISE; FEMALE; HEALTH STATUS; HUMANS; MALE; NUTRITION PHYSIOLOGY; OBESITY; QUALITY OF LIFE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 21644477666     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2005.01607.x     Document Type: Article

References (38)

1. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 2003; 37:55-56.
2. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. Journal of Clinical Psychiatry 1997; 58:7-12.
3. Tollefson GD, Beasley CM, Tran P et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997; 154:457-465.
4. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156:1686-1696.
5. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank BI. Olanzapine: weight gain and therapeutic efficacy. Journal of Clinical Psychopharmacology 1999; 19:273-274.
6. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an over-view of pivotal clinical trials. Journal of Clinical Psychiatry 1997; 58:13-17.
7. Zipursky RB, Gu H, Green AI et al. Clinical correlates of weight gain in first episode patients treated with olanzapine. Schizophrenia Research 2003; 60:372.
8. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry 2001; 62:92-100.
9. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. Journal of Clinical Psychiatry 2001; 6:41-44.
10. Ruschena D, Mullen PE, Burgess P et al. Sudden death in psychiatric patients. British Journal of Psychiatry 1998; 172:331-336.
11. Lambert JR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Medical Journal of Australia 2003; 178:S67-S70.
12. Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 2001; 46:549-555.
13. Glick ID, Fryburg D, O'Sullivan RL, Sin C, Simpson G. Ziprasidone's benefits versus Olanzapine on weight and insulin resistance. American Psychiatric Association Annual Meeting New Research Poster Session 261, New Orleans, LA, 8 May 2001.
14. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001; 158:765-774.
15. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry 2003; 64:598-604.
16. Alison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 2001; 62:22-31.
17. Seidell JC. Society and personal costs of obesity. Experimental and Clinical Endocrinology and Diabetes 1998; 106:7-9.
18. Baptista T. Body weight gain induced by antipsychotic drugs. Acta Psychiatric Scandinavica 1999; 100:3-16.
19. McIntyre R, Mancini M, Basile V. Mechanisms of antipsychotic-induced weight gain. Journal of Clinical Psychiatry 2001; 62:23-29.
20. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatindine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. European Neuropsychopharmacology 2003; 13:81-85.
21. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. European Neuropsychopharmacology 2001; 11:181-182.
22. Baruch R, Poulin M, Thakur A. Amantadine induces weight loss in patients treated with olanzapine. Schizophrenia Research 2002; 53:159.
23. Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23:144-146.
24. Poyurovsky M, Pashinian A, Gil-Ad I et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry 2002; 159:1058-1060.
25. Tafunski T, Chojnacka H. Sibutramine-associated psychotic episode. American Journal of Psychiatry 2000; 157:2056-2057.
26. Dinan TG, Tobin A. Orlistat in the management of antipsychotic-induced weight gain: two case reports. Journal of Serotonin Research 2001; 7:14-15.
27. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. Journal of Clinical Psychopharmacology 2000; 20:716-717.
28. Hilger E, Quiner S, Ginzel I. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. Journal of Clinical Psychopharmacology 2002; 22:68-70.
29. Birt J. Management of weight gain associated with antipsychotics. Annals of Clinical Psychiatry 2003; 15:49-58.
30. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International Clinical Psychopharmacology 2002; 17:145-160.
31. Menza M, Vreeland B, Minsky S, Gara M, Radler D, Sakowitz RD. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. Journal of Clinical Psychiatry 2004; 65:471-477.
32. Centorrino F, Wurtzmann JJ, Duca KK et al. Comprehensive weight loss programs for overweight subjects treated with atypical antipsychotics. Poster presented at 155th American Psychiatric Association Annual Meeting, Philadelphia, PA, 18-23 May 2002.
33. Ball MP, Coons VB, Buchanan RW. A program for treating Olanzapine-related weight gain. Psychiatric Services 2001; 52:967-969.
34. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship 2003; 35:237-241.
35. Nguyen CT, Ortiz T, Franklin D, Yu B, Maguire GA. Nutritional education in minimising weight gain associated with antipsychotic therapy. NR158. Presented at the 154th American Psychiatric Association Annual Meeting, 7 May, 2001; New Orleans.
36. Guy W. ECDEU assessment manual for psychopharmacology, Rev ed. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.
37. Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry 2001; 46:549-555.
38. Barham P. Manfred Bleuler and the understanding of psychosis. In: Ellwood, J, ed. Psychosis: understanding and treatment. Vol 1. London, UK: University of London, Goldsmiths' College, 1995:23-33.